J&J, Pfizer Alzheimer’s Study Will Be Presented in Early October
Researchers will present the results of two late-stage studies on Johnson & Johnson (JNJ) and Pfizer Inc. (PFE)’s experimental drug for Alzheimer’s disease, bapineuzumab, at the American Neurological Association meeting in early October.
The findings of the two studies will be presented in Boston on Oct. 8 in a session dedicated to immune-based treatments for neurological disorders, according to the meeting program posted on the neurological association’s website. The results, if positive, could lead the companies to file for U.S. Food and Drug Administration approval of the medicine.
To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.